PMID- 37385125
OWN - NLM
STAT- MEDLINE
DCOM- 20230711
LR  - 20230718
IS  - 1873-376X (Electronic)
IS  - 1570-0232 (Linking)
VI  - 1226
DP  - 2023 Jul 15
TI  - Identification of chemical constituents of Qingjin Yiqi granules and comparative 
      study on pharmacokinetics of 23 main bioactive components in normal and Lung-Qi 
      deficiency rats by UPLC-MS/MS method.
PG  - 123802
LID - S1570-0232(23)00212-X [pii]
LID - 10.1016/j.jchromb.2023.123802 [doi]
AB  - Qingjin Yiqi granules (QJYQ granules) are hospital preparations derived from 
      ancient prescriptions under the guidance of academician Zhang Boli; they have the 
      effect of invigorating qi and nourishing yin, strengthening the spleen and 
      harmonizing the middle, clearing heat, and drying dampness, and are mainly used 
      for patients with coronavirus disease 2019 (COVID-19) during the recovery period. 
      However, their chemical constituents and pharmacokinetic characteristics in vivo 
      have not been systematically investigated. In this study, 110 chemical 
      constituents of QJYQ granules were identified using ultra-high-performance liquid 
      chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS), and a 
      fast and sensitive ultra-high-performance liquid chromatography-mass spectrometry 
      method was developed and validated for the target analytes. A rat model of 
      lung-qi deficiency was established by subjecting mice to passive smoking combined 
      with cold baths, and 23 main bioactive components of QJYQ granules were analyzed 
      in normal and model rats after oral administration. The results showed that, 
      compared to the normal group, there were significant differences in the 
      pharmacokinetics of baicalin, schisandrin, ginsenoside Rb1, naringin, hesperidin, 
      liquiritin, liquiritigenin, glycyrrhizic acid, and hastatoside in the model rats 
      (P < 0.05), indicating that the in vivo processes of the above components changed 
      under pathological conditions, suggesting that they may have pharmacological 
      effects as active components. This study has helped identify QJYQ particulate 
      substances and further supports their clinical application..
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Li, Guotong
AU  - Li G
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin 301617, China; Tianjin Modern Innovation 
      Chinese Medicine Technology Co., Ltd., Tianjin 300380, China.
FAU - Wang, Xinrui
AU  - Wang X
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin 301617, China; Tianjin Modern Innovation 
      Chinese Medicine Technology Co., Ltd., Tianjin 300380, China.
FAU - Luo, Lifei
AU  - Luo L
AD  - Tianjin Modern Innovation Chinese Medicine Technology Co., Ltd., Tianjin 300380, 
      China.
FAU - Zhang, Han
AU  - Zhang H
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin 301617, China.
FAU - Song, Xinbo
AU  - Song X
AD  - Tianjin Modern Innovation Chinese Medicine Technology Co., Ltd., Tianjin 300380, 
      China.
FAU - Zhang, Jingze
AU  - Zhang J
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin 301617, China; Tianjin Modern Innovation 
      Chinese Medicine Technology Co., Ltd., Tianjin 300380, China. Electronic address: 
      zhangjingze1977@163.com.
FAU - Liu, Dailin
AU  - Liu D
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin 301617, China; Tianjin Modern Innovation 
      Chinese Medicine Technology Co., Ltd., Tianjin 300380, China. Electronic address: 
      dailinlch@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230619
PL  - Netherlands
TA  - J Chromatogr B Analyt Technol Biomed Life Sci
JT  - Journal of chromatography. B, Analytical technologies in the biomedical and life 
      sciences
JID - 101139554
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Animals
MH  - Rats
MH  - Chromatography, High Pressure Liquid/methods
MH  - Chromatography, Liquid
MH  - *COVID-19
MH  - *Drugs, Chinese Herbal/chemistry
MH  - Lung/chemistry
MH  - Qi
MH  - Tandem Mass Spectrometry/methods
OTO - NOTNLM
OT  - Chemical composition
OT  - Lung-qi deficiency
OT  - Pharmacokinetics
OT  - Qingjin Yiqi Granules
OT  - UPLC-MS/MS
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/30 01:06
MHDA- 2023/07/11 06:42
CRDT- 2023/06/29 18:07
PHST- 2023/03/06 00:00 [received]
PHST- 2023/05/28 00:00 [revised]
PHST- 2023/06/14 00:00 [accepted]
PHST- 2023/07/11 06:42 [medline]
PHST- 2023/06/30 01:06 [pubmed]
PHST- 2023/06/29 18:07 [entrez]
AID - S1570-0232(23)00212-X [pii]
AID - 10.1016/j.jchromb.2023.123802 [doi]
PST - ppublish
SO  - J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 15;1226:123802. doi: 
      10.1016/j.jchromb.2023.123802. Epub 2023 Jun 19.